Contents

Part I  General

I.1  History and Principles of Hybrid Imaging ............................. 3
    James A. Patton

I.2  Normal Distribution, Variants, Pitfalls, and Artifacts ................. 35
    Ora Israel and Dominique Delbeke

Part II  Clinical Applications in Oncology

II.1  Tumors of the Central Nervous System ................................. 99
    Aaron C. Jessop, Ronald C. Walker, and Dominique Delbeke

II.2  Hybrid Imaging of Head and Neck Malignancies ..................... 137
    Arie Gordin, Marcelo Daitzchman, and Ora Israel

II.3  Lung Cancer ................................................................. 171
    Ronald C. Walker, Laurie B. Jones-Jackson, Aaron C. Jessop,
    and Dominique Delbeke

II.4  Breast Cancer ............................................................... 217
    Simona Ben-Haim and Vineet Prakash

II.5  Colorectal Cancer ......................................................... 261
    Dominique Delbeke and Ronald C. Walker

II.6  18F-FDG PET/CT in Tumors of the Gastrointestinal Tract: Esophageal
      and Gastric Cancer and Gastrointestinal Stromal Tumors (GIST) ........ 293
    Rachel Bar-Shalom and Ludmila Guralnik

II.7  Hepatobiliary and Pancreatic Malignancies ............................ 331
    Dominique Delbeke and Ronald C. Walker

II.8  Gynecological Tumors ..................................................... 383
    Farrokh Dehdashti and Barry A. Siegel
II.9 Hybrid Imaging in Malignancies of the Urinary Tract, Prostate, and Testicular Cancers
Martine Klein and Marina Orevi

II.10 Thyroid Cancer
Heather A. Jacene, Sibyll Goetze, and Richard L. Wahl

II.11 Endocrine Tumors
Yodphat Krausz

II.12 Lymphoma
Michal Weiler-Sagie and Ora Israel

II.13 Melanoma
Ronald C. Walker, Laurie B. Jones-Jackson, Aaron C. Jessop, and Dominique Delbeke

II.14 Malignancy of the Bone: Primary Tumors, Lymphoma, and Skeletal Metastases
Einat Even-Sapir, Gideon Flusser, and Arye Blachar

II.15 Pediatric Applications for PET/CT and SPECT/CT
Helen R. Nadel and Angela T. Byrne

Part III Other Clinical Applications

III.1 Cardiac Hybrid Imaging (PET/CT and SPECT/CT): Assessment of CAD
Gabriel Vorobiof, Zohar Keidar, Sharmila Dorbala, and Marcelo F. Di Carli

III.2 Hybrid Imaging of Benign Skeletal Diseases
Einat Even-Sapir, Hedva Lerman, Gideon Flusser, and Arye Blachar

III.3 Infectious and Inflammatory Diseases
Christopher J. Palestro, Zohar Keidar, and Charito Love

Subject Index
### Expanded Contents

#### Part I  General

| I.1 History and Principles of Hybrid Imaging | 3 |
| Introduction | 3 |
| Single Photon Emission Computed Tomography | 3 |
| Data Acquisition | 4 |
| SPECT Image Formation | 6 |
| Positron Emission Tomography | 13 |
| PET Detectors | 14 |
| 2D Versus 3D Imaging | 16 |
| Data Acquisition and Image Reconstruction | 16 |
| Time-of-Flight PET | 18 |
| Quantitative Techniques | 18 |
| X-Ray Computed Tomography | 21 |
| SPECT/CT and PET/CT | 24 |
| Clinical SPECT/CT Systems | 26 |
| Clinical PET/CT Systems | 27 |
| Contrast Agents | 27 |
| Beam-Hardening Artifacts | 28 |
| Physiological Motion | 28 |
| Radiation Dosimetry Considerations | 28 |
| Quality Assurance | 29 |
| Conclusions | 31 |
| References | 32 |

| I.2 Normal Distribution, Variants, Pitfalls, and Artifacts | 35 |
| PET/CT Imaging with $^{18}$F-Fluorodeoxyglucose | 35 |
| Normal $^{18}$F-FDG Distribution and Physiologic Variants | 35 |
| Pitfalls and Artifacts on $^{18}$F-FDG Imaging | 37 |
| Benign Processes Accumulating $^{18}$F-FDG | 38 |
| Treatment-Related Processes Accumulating $^{18}$F-FDG | 38 |
| Summary | 39 |
| Physiologic Distribution of Other PET Tracers | 40 |
| $^{18}$F-Fluoride | 40 |
| $^{18}$F-Fluorothymidine | 40 |
| $^{11}$C-Choline | 41 |
| Fluorocholine $^{11}$C-Acetate | 41 |
Physiologic Distribution of SPECT/CT Imaging Tracers. ........................................... 43

I.2.1 Normal $^{18}$F-FDG Distribution (DICOM Images on DVD) .................................. 48
I.2.2 Physiologic $^{18}$F-FDG Uptake in aSymmetric Vocal Cord ...................................... 56
I.2.3 Rebound Thymic Hyperplasia ...................................................................................... 58
I.2.4 Recurrent Hodgkin’s Disease and Abdominal Wall Muscular Uptake in a Patient with Nausea and Vomiting ................................................................. 61
I.2.5 Diffuse Muscular Uptake in a Non-fasting Patient ....................................................... 63
I.2.6 Pericarditis and Crossed Ectopic Kidney .................................................................. 66
I.2.7 $^{18}$F-FDG Uptake in Menstruating Uterus and Right Ovary at Mid-Menstrual Cycle ................................................................. 70
I.2.8 Hodgkin’s Disease and Lactating Breast ................................................................ 73
I.2.9 Brown Adipose Tissue Above and Below the Diaphragm ....................................... 75
I.2.10 Normal Distribution of $^{18}$F-FLT in a Patient with Menetrier’s Disease .................. 80
I.2.11 $^{131}$I-iodine: Remnant Left Lobe Thyroid Tissue on Post-Ablation Study ................ 82
I.2.12 $^{131}$I-iodine: Physiological Uterine Uptake During Menstruation on Post-Ablation Study ................................................................. 84
I.2.13 $^{123}$I MIBG: Right Adrenal Pheochromocytoma and Dilated Right Renal Pelvis .......... 87
I.2.14 $^{99m}$Tc-sestamibi: Left Parathyroid Adenoma, Atrophy of Right Submandibular Gland and Slightly Enlarged Right Lobe of the Thyroid ........................................ 91

References .......................................................................................................................... 94

Part II Clinical Applications in Oncology ................................................................. 97

II.1 Tumors of the Central Nervous System .................................................................... 99
Introduction ......................................................................................................................... 99
Physiologic Distribution of $^{18}$F-FDG in the CNS ....................................................... 100
Initial Evaluation and Staging of Primary Cerebral Tumors ........................................... 101
Evaluation of Treated Primary Cerebral Tumors .............................................................. 102
Evaluation of Cerebral Metastases .................................................................................... 102
Evaluation of Meningiomas .............................................................................................. 103
Summary ........................................................................................................ 104
Guidelines and Recommendations for the use of $^{18}$F-FDG PET and PET/CT ................................................... 104
Case Presentations ....................................................................................... 105
  II.1.1 Low-grade Glioma (Oligodendroglioma, WHO Grade II) ................................................................. 105
  II.1.2 Recurrent Glioma with Transformation from Low-Grade to High-Grade ............................................. 108
  II.1.3 Primary Lymphoma of CNS .............................................................. 110
  II.1.4 Toxoplasmosis (DICOM Images on DVD) ................................................................................. 113
  II.1.5 Stage IV Non-small Cell Lung Cancer with Cerebral Metastases and Poor FDG Uptake within the Brain due to Hyperglycemia ................................................................. 117
  II.1.6 Right Frontal Cerebral Arteriovenous Malformation ................................................................. 119
  II.1.7 Recurrent Glioblastoma Multiforme with Diminished Uptake in the Right Temporal Region due to Post-therapy Changes and Crossed Cerebellar Diaschisis (DICOM Images on DVD) .... 122
  II.1.8 Meningioma .................................................................................. 126
  II.1.9 Recurrent Low-grade Glioma Evaluated with $^{11}$C-methionine ..................................................... 131
References .................................................................................................... 134

II.2 Hybrid Imaging of Head and Neck Malignancies ............................................. 137
Introduction .................................................................................................. 137
Staging of Head and Neck Carcinoma .......................................................... 138
Cervical Lymph Node Metastases of Unknown Tumors ................................. 140
Monitoring Response to Therapy ................................................................. 141
Diagnosis and Restaging of Recurrence ....................................................... 142
Planning of Radiotherapy ........................................................................... 142
Summary .................................................................................................... 143
Guidelines and Recommendations for the Use of $^{18}$F-FDG PET and PET/CT ................................................... 143
Case Presentations ....................................................................................... 144
  II.2.1 Neck Metastasis of Unknown Origin ................................................................................. 144
  II.2.2 Cancer of the Larynx with Suspected Lung Metastases ......................................................... 146
  II.2.3 Recurrent Cancer of the Nasopharynx: PET/CT Guided Biopsy and Diagnosis (DICOM Images on DVD) ................................................................. 149
  II.2.4 Second Primary Cancer of the Esophagus in Patient with Suspected Recurrence of Laryngeal Tumor ................................................................................. 153
  II.2.5 Recurrent Cancer of the Larynx: PET/CT Guided Biopsy and Diagnosis ......................................... 156
  II.2.6 Assessment of the Post-Irradiated Edematous Larynx with PET/CT ............................................ 158
  II.2.7 Cancer of the Base of the Tongue with Normal Size Cervical Metastasis ................................. 160
  II.2.8 Multiple Regional and Distant Metastases in Patient with Advanced Laryngeal Cancer ................................................................................. 162
  II.2.9 Benign FDG-avid Lesion: Warthin’s Tumor of Parotid Gland ..................................................... 166
References .................................................................................................... 168
II.3 Lung Cancer .................................................... 171

Introduction .................................................... 171
Indeterminate Pulmonary Nodules ........................................... 171
Non-surgical Evaluation of Pulmonary Nodules ............................ 172
\(^{18}\)F-FDG PET/CT for Evaluation of Pulmonary Nodules ................. 173
Guidelines for Evaluation of Indeterminate Nodules ..................... 174
Non-Small-Cell Lung Carcinoma (NSCLC) ................................ 175
TNM Staging of NSCLC .............................................. 175
\(^{18}\)F-FDG Imaging for Staging of NSCLC at Presentation:
Comparison to CT ................................................. 176
Detection of Extra-Thoracic Metastases ................................... 177
Impact of \(^{18}\)F-FDG Imaging on Management of NSCLC at Presentation .. 178
\(^{18}\)F-FDG Imaging for Monitoring Therapy of NSCLC .................. 178
Detection of Recurrence and Restaging with \(^{18}\)F-FDG PET or PET/CT .... 179
Summary .......................................................... 179
Small-Cell Lung Carcinoma (SCLC) ..................................... 180
\(^{18}\)F-FDG PET and PET/CT for Staging, Restaging, and Assessment
of Treatment Response of SCLC ...................................... 180
Summary .......................................................... 181
Malignant Pleural Mesothelioma ........................................... 181
Introduction ........................................................ 181
\(^{18}\)F-FDG Imaging of MPM ........................................ 183
Assessment of Metabolic Response to Treatment of MPM ............... 184
Summary .......................................................... 184
Guidelines and Recommendations for the Use of F-FDG PET and PET/CT . 184

Case Presentations ................................................. 186

II.3.1 Solitary Pulmonary Nodule with Moderate \(^{18}\)F-FDG Uptake:
Solitary Metastasis .................................................. 186
II.3.2 Solitary Pulmonary Mass with Moderate \(^{18}\)F-FDG Uptake:
Granuloma .......................................................... 188
II.3.3 Solitary Pulmonary Nodule with Intense \(^{18}\)F-FDG Uptake:
Primary Lung Cancer ................................................ 190
II.3.4 Multi-focal Primary Lung Cancer: Bronchoalveolar Cell
Carcinoma .......................................................... 192
II.3.5 Restaging of Recurrent NSCLC: Recurrent TNM Stage IIA ........ 194
II.3.6 Pre-operative Staging of NSCLC with \(^{18}\)F-FDG PET/CT:
Stage IIA ........................................................... 197
II.3.7 Pre-operative Staging of NSCLC with \(^{18}\)F-FDG PET/CT:
Stage IIB and Adenomatous Polyp of the Transverse Colon .......... 199
II.3.8 Pre-operative Staging of NSCLC with \(^{18}\)F-FDG PET/CT:
Stage IV and Radiation Pneumonitis (DICOM Images on DVD) .... 201
II.3.9 Pre-operative Staging of SCLC with \(^{18}\)F-FDG PET/CT:
Limited-Stage Disease ............................................. 205
II.3.10 Pre-treatment Staging of Malignant Pleural Mesothelioma with
\(^{18}\)F-FDG PET/CT (DICOM Images on DVD) .................... 207
II.3.11 Use of \(^{18}\)F-FDG PET/CT for Radiation Treatment Planning of
NSCLC ............................................................ 211

References .......................................................... 213
II.4 Breast Cancer ................................. 217
  Introduction ........................................ 217
  18F-FDG PET and PET/CT for the Detection and Staging of Breast Cancer ....... 218
  18F-FDG PET and PET/CT for the Detection of Metastatic Breast Cancer ......... 219
  18F-FDG PET and PET/CT for the Detection and Staging of Recurrent Breast Cancer .......................................................... 219
  18F-FDG Imaging to Monitor Therapy of Breast Cancer .............................. 220
  18F-FDG PET/CT for Radiation Therapy Planning in Breast Cancer .............. 221
  Summary ................................................. 221
  Guidelines and Recommendations for the Use of 18F-FDG PET and PET/CT ........ 222

Case Presentations .................................. 223
  II.4.1 Unsuspected Breast Primary Cancer ................................................. 223
  II.4.2 Metastatic Breast Cancer to Omentum, Peritoneum, and Ovaries with Partial Response to Treatment ................................. 226
  II.4.3 Metastatic Breast Cancer to Liver, T8 Vertebral Body, Right Femur, and Acetabulum ..................................................... 232
  II.4.4 Recurrent Left Breast Cancer with Regional Metastases to Left Chest Wall and Synchronous Right Thyroid Papillary Cancer (DICOM Images on DVD) ........................................... 236
  II.4.5 Solitary Hepatic Metastasis, Right Chest Wall Breast Cancer Recurrence, and Right Apical Lung Metastasis Causing Brachial Plexopathy .......................................................... 242
  II.4.6 Metastatic Breast Cancer to Bones, Left Lung, and Pleura: Good Response to Therapy in Left Lung and Pleura; Partial Response to Therapy in Bones (DICOM Images on DVD) .............. 246

References ............................................. 259

II.5 Colorectal Cancer .............................. 261
  Introduction ............................................. 261
  18F-FDG PET and PET/CT for Screening and Diagnosis of Colorectal Carcinoma ........................... 261
  18F-FDG PET and PET/CT in the Initial Staging of Colorectal Carcinoma ........ 262
  18F-FDG PET and PET/CT for Assessment of Recurrent Colorectal Carcinoma ............................................................................. 262
  Detection and Restaging of Recurrence .................................................... 262
  Impact on Management and Cost Analysis in Patients with Recurrent Disease .......................................................... 263
  18F-FDG Imaging for Monitoring Therapy Response of Colorectal Carcinoma ........................................................................ 265
  Systemic Chemotherapy ................................................ 265
  Radiation Therapy ........................................... 265
  Regional Therapy to the Liver ................................................................. 266
  Summary ..................................................... 266
  Guidelines and Recommendations for the Use of 18F-FDG PET and PET/CT ........ 266
Case Presentations ........................................................... 268
II.5.1 Incidental Primary Transverse Colon Carcinoma in a Patient
with Lung Cancer and Malignant Fibrohistiocytoma (DICOM
Images on DVD) .............................................................. 268
II.5.2 Primary Metastatic Rectal Carcinoma ................................ 274
II.5.3 Colon Cancer with Hepatic Metastases ......................... 279
II.5.4 Local Recurrence and Metastatic Retroperitoneal Lymph Nodes
(DICOM Images on DVD) .................................................. 281
II.5.5 Colon Cancer with Pulmonary Metastases .................... 286
II.5.6 Mucinous Adenocarcinoma of the Colon ...................... 288
References ....................................................................... 290

II.6 $^{18}$F-FDG PET/CT in Tumors of the Gastrointestinal Tract:
Esophageal and Gastric Cancer and Gastrointestinal Stromal
Tumors (GIST) ....................................................................... 293
$^{18}$F-FDG Imaging in Esophageal Cancer .............................. 293
Introduction ........................................................................ 293
$^{18}$F-FDG Imaging for Staging of Esophageal Cancer .......... 294
$^{18}$F-FDG Imaging for Monitoring Response to Treatment
of Esophageal Cancer .......................................................... 295
$^{18}$F-FDG Imaging for Diagnosis of Recurrent Esophageal Cancer 296
$^{18}$F-FDG Imaging in Gastric Cancer .................................... 296
Introduction ........................................................................ 296
$^{18}$F-FDG Imaging for Diagnosis and Staging of Gastric Cancer 297
$^{18}$F-FDG Imaging for Monitoring Response to Treatment of Gastric
Cancer .............................................................................. 298
$^{18}$F-FDG Imaging for Diagnosis of Recurrent Gastric Cancer .... 298
$^{18}$F-FDG Imaging in Gastrointestinal Stromal Tumors ....... 299
Introduction ........................................................................ 299
$^{18}$F-FDG Imaging at Initial Diagnosis of GIST ................. 300
$^{18}$F-FDG Imaging for Monitoring Response to Treatment
of GIST ........................................................................... 300
Guidelines and Recommendations for the Use of $^{18}$F-FDG PET and
PET/CT in Esophageal Cancer ............................................. 301
Case Presentations ............................................................. 302
II.6.1 Distal Esophageal Cancer at Staging: Loco-regional
Metastatic Adenopathy at the Level of the Gastro-hepatic
Ligament and Distant Non-regional Metastasis in Left
Pre-tracheal Lymph Node (DICOM Images on DVD) .......... 302
II.6.2 Increase Focal $^{18}$F-FDG Gastric Uptake at Site of Upper
Anastomosis, Most Probably due to Physiologic Uptake
or a Mild Inflammatory Process ........................................... 307
II.6.3 Primary Gastric Cancer with no Evidence of Metastases;
Degenerative Changes in Cervical Spine (DICOM Images
on DVD) ........................................................................ 309
II.6.4 Adenocarcinoma of Gastro-esophageal Junction with Nodal
Metastasis in Porta-hepatic Region and Inflammatory Lung
Infiltrate ........................................................................ 315
II.6.5 Para-rectal GIST with no Evidence for Metastases: Complete Metabolic Response to treatment with Gleevec on $^{18}$F-FDG-PET and Partial Response with Residual Para-rectal Mass on CT ...... 319

II.6.6 Recurrent GIST within Multiple Omental and Peritoneal Metastases .............................................. 322

References .................................................. 327

II.7 Hepatobiliary and Pancreatic Malignancies ........................................ 331

Hepatobiliary Neoplasms ........................................ 331
Pancreatic Neoplasms .......................................... 332
Imaging of Hepatobiliary and Pancreatic Neoplasms .......... 332
Hepatic Metastases ........................................... 334
$^{18}$F-FDG PET/CT Imaging of Hepatic Metastases .......... 334
Hepatocellular Carcinoma .................................... 334
$^{18}$F-FDG PET/CT for Diagnosis and Staging of HCC .... 335
$^{11}$C-Acetate Imaging of HCC ................................ 335
Cholangiocarcinoma ........................................... 336
$^{18}$F-FDG PET/CT for Diagnosis and Staging of Cholangiocarcinoma ... 336
Gallbladder Carcinoma ........................................ 337
$^{18}$F-FDG PET/CT for Diagnosis and Staging of Gallbladder Carcinoma ... 337
$^{18}$F-FDG PET/CT Monitoring Therapy of Hepatic Tumors .... 337
Pancreatic Cancer ............................................ 338
$^{18}$F-FDG PET/CT for Preoperative Diagnosis of Pancreatic Carcinoma ... 339
$^{18}$F-FDG PET/CT for Staging of Pancreatic Carcinoma ........ 340
$^{18}$F-FDG PET/CT in the Post-therapy Setting ............... 340
Impact of $^{18}$F-FDG PET/CT on Management of Patients with Pancreatic Carcinoma .................................... 340
Limitations of $^{18}$F-FDG Imaging ........................... 341
Summary .................................................... 341
Guidelines and Recommendations for the Use of $^{18}$F-FDG PET and PET/CT ........................................... 342

Case Presentations ............................................ 343

II.7.1 Hepatocellular Carcinoma (DICOM Images on DVD) .................. 343
II.7.2 Cholangiocarcinoma .................................. 350
II.7.3 Gallbladder Carcinoma ................................ 355
II.7.4 Pancreatic Carcinoma (DICOM Images on DVD) .................. 360
II.7.5 Klatskin’s Tumor and Acute Pancreatitis .................... 366
II.7.6 Cavernous Hemangioma ................................ 371
II.7.7 Focal Nodular Hyperplasia ............................. 373
II.7.8 Monitoring Therapy of Hepatic Metastases Treated with $^{90}$Y-microspheres ..................................... 377

References .................................................... 379

II.8 Gynecological Tumors ....................................... 383

Introduction ................................................ 383
Cervical Cancer .............................................. 383
$^{18}$F-FDG PET/CT in Staging Cervical Cancer .................. 383
$^{18}$F-FDG PET/CT in Directing Therapy in Cervical Cancer .... 384
**Case Presentations**

II.9.1 Renal Cell Carcinoma with Left Pulmonary Metastasis ............... 419
II.9.2 RCC with Recurrent Skeletal Metastasis (DICOM Images on DVD) .......... 422
II.9.3 Muscle Invasive TCC of Bladder with Single Nodal Metastasis ....... 426
II.9.4 Muscle Invasive TCC of Bladder with Bilateral Pelvic Lymph Nodes Metastases (DICOM Images on DVD) .................. 429
II.9.5 Primary Prostate Cancer with Right Obturator Nodal Metastasis ........ 434
II.9.6 Local Recurrence of Prostate Cancer and Paget’s Disease of Right Iliac Bone ................................. 436
II.9.7 Metastatic Seminoma Achieving a Complete Remission .............. 438

**References** .................................................. 441

**II.10 Thyroid Cancer** ................................................. 445

Introduction .......... 445
Differentiated Thyroid Cancer ................................. 446
Radioiodine Whole-Body Scintigraphy with SPECT/CT ................. 446
\(^{18}\text{F}-\text{FDG PET/CT}................................. 446
Hürthle Cell Carcinoma ......................... 447
Anaplastic Thyroid Cancer ......................... 448
Medullary Thyroid Cancer .......... 448
Thyroid Incidentalomas on \(^{18}\text{F-FDG PET/CT}...... 449
Guidelines and Recommendations for the Use of \(^{18}\text{F-FDG PET} and PET/CT .......................................... 449

**Case Presentations** .............................................. 450

II.10.1 Recurrent Papillary Thyroid Carcinoma in Right Upper Paratracheal Lymph Nodes (DICOM Images on DVD) ................. 450
II.10.2 Metastatic Papillary Thyroid Cancer, Bilateral Central and Right lateral Neck Lymph Nodes (DICOM Images on DVD) .... 453
II.10.3 Persistent, Iodine-avid Hürthle Cell Carcinoma in Left Iliac/Sacral Metastasis ........ 458
II.10.4 Anaplastic Thyroid Carcinoma in the Thyroid Gland and Possible Metastasis in a Left Parotid Lymph Node .......... 460
II.10.5 Medullary Thyroid Cancer with Metastatic Left Neck Lymphadenopathy, Active and Treated Skeletal Metastases, and Treated Hepatic Metastases ................. 463
II.10.6 Recurrent Medullary Thyroid Cancer with Right Paratracheal and Left Level II Lymph Nodes, Skeletal Metastases, and Physiologic Scalene Muscle \(^{18}\text{F-FDG Uptake} ....... 465
II.10.7 Recurrent Melanoma of the Right Nasal Cavity Mucosa and Papillary Thyroid Carcinoma ........ 468

**References** .................................................. 471

**II.11 Endocrine Tumors** ............................................ 475

Introduction .......... 475
Imaging Protocols ........ 476
SPECT/CT and PET/CT Tracers for Imaging of NE Tumors .......... 476
SPECT/CT and PET/CT of GEP Tumors ................................................................. 478
SPECT/CT and PET/CT of Neural Crest Tumors ............................................. 479
SPECT/CT of Parathyroid Adenoma ................................................................. 481
Summary ............................................................................................................ 482
Case Presentations ............................................................................................. 483
II.11.1 Well-differentiated Small Intestine Neuroendocrine Tumor with Mesenteric Metastasis (DICOM Images on DVD) ................................................................. 483
II.11.2 VIPoma in Body of the Pancreas .............................................................. 488
II.11.3 Pancreatic Neuroendocrine Carcinoma with Disseminated Hepatic and Skeletal Metastases Expressing High Density of Somatostatin Receptors ................................................................. 491
II.11.4 Suspected Recurrence of Pheochromocytoma in Left Adrenal Bed ........ 494
II.11.5 123I-MIBG Avid Pheochromocytoma Metastatic to Lungs and Liver .... 498
II.11.6 Left Upper Parathyroid Adenoma in Posterior Location between the Trachea and Esophagus ................................................................. 503
II.11.7 Ectopic Parathyroid Adenoma in Mid-anterior Lower Neck ................... 506
II.11.8 68Ga-DOTATOC-avid Neuroendocrine Tumor in Tail of Pancreas .... 508
References ........................................................................................................... 509

II.12 Lymphoma ................................................................................................... 513
Introduction ......................................................................................................... 513
Non-Hodgkin’s Lymphoma ............................................................................... 513
Hodgkin’s Disease ............................................................................................. 515
18F-FDG Imaging for Diagnosis of NHL and HD .............................................. 516
18F-FDG Imaging at Initial Staging of Lymphoma ........................................... 516
18F-FDG Avidity of HD and NHL ..................................................................... 516
Comparative Performance of 18F-FDG Imaging and CT .................................. 516
Diagnosis of Bone Marrow Involvement ......................................................... 517
18F-FDG Staging Criteria in HD and NHL ....................................................... 517
18F-FDG Imaging for Monitoring Therapy Response in Lymphoma ............. 517
Definition of Response ..................................................................................... 517
Timing of 18F-FDG Imaging in Assessing Response to Treatment in Lymphoma ......................................................................................... 518
During and End-of-Treatment 18F-FDG Imaging in Lymphoma ................. 518
18F-FDG Imaging of a Residual Mass ............................................................... 519
Pitfalls in Interpretation ................................................................................... 519
18F-FDG Imaging for Diagnosis and Restaging of Lymphoma Recurrence ... 520
Summary ............................................................................................................ 520
Guidelines and Recommendations for the Use of 18F-FDG-PET and PET/CT ................................................................................................. 521
Case Presentations ............................................................................................. 523
II.12.1 NHL-DLCL of the Spleen (with local invasion to LN in splenic hilum and to tail of pancreas) (DICOM Images on DVD) ................................................................. 523
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>II.12.2 NHL-DLCL Stage IV: Good Response to Treatment</td>
<td>529</td>
</tr>
<tr>
<td>II.12.3 HD, Nodular Sclerosis Type Stage III: Good Early Response at Mid-treatment (DICOM Images on DVD)</td>
<td>532</td>
</tr>
<tr>
<td>II.12.4 Recurrent Small Lymphocytic NHL and Infection in Right Groin</td>
<td>536</td>
</tr>
<tr>
<td>II.12.5 HD, Refractory to First Line Chemotherapy: CR after Salvage Therapy and AHCT</td>
<td>540</td>
</tr>
<tr>
<td>II.12.6 Recurrent Follicular Grade II NHL and Gastritis</td>
<td>542</td>
</tr>
<tr>
<td>II.12.7 Early Relapse of HD</td>
<td>544</td>
</tr>
<tr>
<td>II.12.8 Recurrent Follicular Grade II NHL</td>
<td>547</td>
</tr>
<tr>
<td>II.12.9 HD in Complete Remission: Transient Foci of Increased $^{18}$F-FDG Activity due to Inflammation</td>
<td>550</td>
</tr>
<tr>
<td>References</td>
<td>552</td>
</tr>
<tr>
<td>II.13 Melanoma</td>
<td>555</td>
</tr>
<tr>
<td>Introduction</td>
<td>555</td>
</tr>
<tr>
<td>Cutaneous Melanoma</td>
<td>555</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>555</td>
</tr>
<tr>
<td>Staging</td>
<td>556</td>
</tr>
<tr>
<td>Detection of Recurrence and Restaging with $^{18}$F-FDG PET and PET/CT</td>
<td>559</td>
</tr>
<tr>
<td>Choroidal Melanoma</td>
<td>561</td>
</tr>
<tr>
<td>Summary</td>
<td>562</td>
</tr>
<tr>
<td>Guidelines and Recommendations for the Use of $^{18}$F-FDG PET and PET/CT</td>
<td>562</td>
</tr>
<tr>
<td>Case Presentations</td>
<td>563</td>
</tr>
<tr>
<td>II.13.1 Metastatic Melanoma with Cerebral Metastases Seen on CT Only</td>
<td>563</td>
</tr>
<tr>
<td>II.13.2 Metastatic Melanoma s/p Regional Lymph Node Dissection</td>
<td>565</td>
</tr>
<tr>
<td>II.13.3 Metastatic Melanoma to the Right Ventricle and Pulmonary Emboli (DICOM Images on DVD)</td>
<td>567</td>
</tr>
<tr>
<td>II.13.4 Choroidal Melanoma</td>
<td>570</td>
</tr>
<tr>
<td>II.13.5 No Evidence of Recurrence in a Patient Treated with Vaccine.</td>
<td>573</td>
</tr>
<tr>
<td>II.13.6 Widely Metastatic Melanoma including the Mesentery (DICOM Images on DVD)</td>
<td>575</td>
</tr>
<tr>
<td>II.13.7 SPECT/CT of a Cervical Sentinel Lymph Node</td>
<td>579</td>
</tr>
<tr>
<td>References</td>
<td>581</td>
</tr>
<tr>
<td>II.14 Malignancy of the Bone: Primary Tumors, Lymphoma, and Skeletal Metastases</td>
<td>583</td>
</tr>
<tr>
<td>Skeletal Metastases, Bone Lymphoma, and Multiple Myeloma</td>
<td>583</td>
</tr>
<tr>
<td>$^{18}$F-FDG PET/CT for Diagnosis of Malignant Skeletal Lesions</td>
<td>583</td>
</tr>
<tr>
<td>$^{18}$F-FDG PET/CT for Monitoring Response to Therapy</td>
<td>584</td>
</tr>
<tr>
<td>Advantages of $^{18}$F-FDG PET/CT in Malignant Skeletal Involvement</td>
<td>584</td>
</tr>
<tr>
<td>Summary</td>
<td>584</td>
</tr>
</tbody>
</table>
Primary Skeletal Malignancies .................................................. 585
\(^{18}\)F-FDG PET/CT for Diagnosis of Primary Skeletal Tumors .......... 585
\(^{18}\)F-FDG PET/CT for Staging Primary Skeletal Tumors .......... 585
\(^{18}\)F-FDG PET/CT for Monitoring Response to Therapy .......... 586
Summary ................................................................. 586

Case Presentations ................................................................. 587
II.14.1 Lung Cancer with Direct Extension to Bone and Distant Skeletal Metastases (DICOM Images on DVD) .......... 587
II.14.2 Marrow-based and Cortical Skeletal Metastases before and with Partial Response after Treatment, and Hepatic Metastases . . . 592
II.14.3 Lung Cancer with Extensive Skeletal Metastatic Spread and Invasion of the Epidural Space at T11 .......... 598
II.14.4 Lymphoma with Skeletal Involvement and Suspected Involvement of the Left S1 Neural Foramen, in addition to Nodal Pleural and Muscular Disease .............. 600
II.14.5 Primary Lymphoma of the Bone ................................ 604
II.14.6 Multiple Myeloma with Active Disease in Rib and Post-radiotherapy Inactive Disease in Vertebra .......... 610
II.14.7 Ewing Sarcoma of the Proximal Femur with Muscular Involvement, Pulmonary Metastases, and Suspected Additional Distant Sites of Disease in Bone and Lymph Nodes (DICOM Images on DVD) .......... 612
References ................................................................. 618

II.15 Pediatric Applications for PET/CT and SPECT/CT ............... 621
Introduction ......................................................................... 621
Neuroblastoma ..................................................................... 621
Sarcoma ............................................................................. 622
Lymphoma .......................................................................... 623
Considerations on Radiation Exposure from PET/CT .................. 624
PET/CT Procedure and Preparation of the Pediatric Patient .......... 625
SPECT/CT Procedure and Preparation of the Pediatric Patient .......... 625
Case Presentations ................................................................. 627
II.15.1 B-Cell Lymphoblastic Lymphoma, Stage IV Disease with Left and Right Face/Neck Disease and Bilateral Skeletal Involvement of the Lower Extremities (DICOM Images on DVD) .......... 627
II.15.2 Multiple GIST Tumors Metastatic to the Liver and Unconfirmed Pulmonary Chondromas .......... 633
II.15.3 Ewing Sarcoma with Solitary Skeletal Metastasis .......... 637
II.15.4 ALL with Diffuse Skeletal Involvement, Renal and GIT Involvement; Post-surgical Changes Related to Previous Rotationplasty for Osteogenic Sarcoma .......... 640
II.15.5 Stage IV Neuroblastoma with Residual Retrocrural Soft Tissue Disease and Skeletal Metastasis in the Sacrum after Treatment and Post-surgical Changes Left Upper Quadrant (DICOM Images on DVD) .......... 645
II.15.6 Occult Calcaneal Stress Fracture .......... 651
References ................................................................. 655
Part II Other Clinical Applications .......................................................... 657

III.1 Cardiac Hybrid Imaging (PET/CT and SPECT/CT): Assessment of CAD . . 659
   Introduction .................................................................................................. 659
   Imaging Protocols for Hybrid Cardiac Imaging ........................................... 659
      CT Imaging for Hybrid Cardiac SPECT/CT and PET/CT ....................... 659
      Cardiac SPECT/CT .................................................................................. 661
      Cardiac PET/CT ..................................................................................... 661
   Quality Control of Cardiac Hybrid Imaging .................................................. 662
   Clinical Applications of Cardiac Hybrid Imaging ...................................... 662
      Diagnosis of CAD Using Cardiac Hybrid Imaging ................................. 662
      Risk Assessment Using Cardiac Hybrid Imaging .................................... 663
      Guiding Management of CAD Using Cardiac Hybrid Imaging ............... 664
   Conclusions ............................................................................................... 665

Case Presentations ........................................................................................ 666
III.1.1 Cardiac SPECT/Low Dose CT for Attenuation Correction: Normal Patient with Misregistration ......................................................... 666
III.1.2 Cardiac PET/Low Dose CT for Attenuation Correction: Normal Patient with Misregistration ................................................................. 668
III.1.3 Cardiac SPECT/CCTA: Hemodynamically Significant Lesion in the Territory of the RCA Related to Stenosis in SVG to RCA ....................... 670
III.1.4 Cardiac SPECT/CCTA: Ischemia in the Inferior Wall Indicating the Hemodynamically Significant Lesion in the RCA ................................. 673
III.1.5 Normal PET MPS with High Calcium Score (> 1,000) ................. 676
III.1.6 Moderate Stenosis in the RCA with Normal PET MPS ..................... 679
   Protocol ....................................................................................................... 679
   References ................................................................................................. 681

III.2 Hybrid Imaging of Benign Skeletal Diseases ........................................ 683
   99mTc-MDP SPECT/CT .............................................................................. 683
   18F-Fluoride PET/CT .................................................................................. 685
   18FDG PET/CT .......................................................................................... 686
   Summary ..................................................................................................... 687
   Case Presentations ....................................................................................... 688
      III.2.1 Incidentally Found Fibrous Dysplasia in the Left Tibia .............. 688
      III.2.2 Parosteal Ossifying Lipoma in the Left Fibula ......................... 691
      III.2.3 Giant Cell Tumor of the Sacral Bone and Presacral Region (DICOM Images on DVD) ................................................................. 694
      III.2.4 Chronic Recurrent Multifocal Osteomyelitis in the Thoracic Spine, Knees, Right Humerus, and Scapula (DICOM Images on DVD) .......... 699
      III.2.5 Osteonecrosis in Both Knees ...................................................... 705
   References ................................................................................................. 708

III.3 Infectious and Inflammatory Diseases .................................................... 711
   Introduction ............................................................................................... 711
   Radionuclide Procedures ............................................................................ 711
Skeletal Scintigraphy .......................................................... 711
67Gallium Scintigraphy ..................................................... 712
Labeled Leukocyte Scintigraphy ........................................... 712
18F-FDG Imaging ............................................................. 713

Case Presentations .......................................................... 714

III.3.1 Right Quadriceps Abscess: 67Ga SPECT/CT .................. 714
III.3.2 Soft Tissue Abscess and Osteomyelitis of the Mandibular
Bone Graft: 67Ga SPECT/CT ............................................ 717
III.3.3 Soft Tissue Infection of the Left Lateral Ankle: 99mTc-MDP
and 111In-WBC SPECT/CT ........................................... 720
III.3.4 Hepatic Abscess: 67Ga SPECT/CT ............................ 724
III.3.5 Osteomyelitis of the Medial Cuneiform and Right First
Metatarsal: 18F-FDG PET/CT ........................................... 726
III.3.6 Infected Right Femoropopliteal Graft: 18F-FDG PET/CT .... 728
III.3.7A Fever of Unknown Origin: 18F-FDG PET/CT (DICOM
Images on DVD) ......................................................... 731
III.3.7B Dental Abscess 18F-FDG PET/CT ............................ 734
III.3.7C Infected Rental Cyst: 18F-FDG PET/CT ..................... 736
III.3.8 Healing Traumatic L3 Vertebral Fracture: 99mTc-MDP
SPECT/CT and 18F-FDG PET/CT (DICOM Images
on DVD) ................................................................. 739

References ........................................................................ 744

Subject Index ...................................................................... 747
Hybrid PET/CT and SPECT/CT Imaging
A Teaching File
Delbeke, D.; Israel, O. (Eds.)
2010, XXX, 762 p. 300 illus. in color. With CD-ROM., Hardcover